Cargando…
FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
BACKGROUND: Two US Food and Drug Administration (FDA)-authorized coronavirus disease 2019 (COVID-19) mRNA vaccines, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna), have demonstrated high efficacy in large phase 3 randomized clinical trials. It is important to assess their effectiveness in a real...
Autores principales: | Pawlowski, Colin, Lenehan, Patrick, Puranik, Arjun, Agarwal, Vineet, Venkatakrishnan, A.J., Niesen, Michiel J.M., O’Horo, John C., Virk, Abinash, Swift, Melanie D., Badley, Andrew D., Halamka, John, Soundararajan, Venky |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238652/ https://www.ncbi.nlm.nih.gov/pubmed/34223401 http://dx.doi.org/10.1016/j.medj.2021.06.007 |
Ejemplares similares
-
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
por: Puranik, Arjun, et al.
Publicado: (2021) -
Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection
por: Niesen, Michiel J M, et al.
Publicado: (2022) -
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
por: Puranik, Arjun, et al.
Publicado: (2022) -
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
por: Puranik, Arjun, et al.
Publicado: (2022) -
Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System
por: Pawlowski, Colin, et al.
Publicado: (2021)